Penack, Olaf http://orcid.org/0000-0003-4876-802X
Abouqateb, Mouad
Peczynski, Christophe
Boreland, William
Gülbas, Zafer
Gedde-Dahl, Tobias
Castilla-Llorente, Cristina
Kröger, Nicolaus http://orcid.org/0000-0001-5103-9966
Eder, Mathias
Rambaldi, Alessandro
Bonifazi, Francesca http://orcid.org/0000-0003-1544-9911
Blau, Igor Wolfgang
Stelljes, Matthias
Dreger, Peter http://orcid.org/0000-0002-7429-8570
Moiseev, Ivan
Schoemans, Hélène
Koenecke, Christian
Peric, Zinaida
Article History
Received: 18 December 2023
Revised: 4 March 2024
Accepted: 5 March 2024
First Online: 15 March 2024
Competing interests
: OP has received honoraria or travel support from Gilead, Jazz, MSD, Novartis, Pfizer and Therakos. He has received research support from Incyte and Priothera. He is member of advisory boards to Equillium Bio, Jazz, Gilead, Novartis, MSD, Omeros, Priothera, Sanofi, Shionogi and SOBI. HS reports having received personal fees from Incyte, Janssen, Novartis, Sanofi and from the Belgian Hematological Society (BHS), as well as research grants from Novartis and the BHS, all paid to her institution. She has also received non-financial support from Gilead, Pfizer, the EBMT (European Society for Blood and Marrow transplantation) and the CIBMTR (Center for International Bone Marrow Transplantation Research). IM received honoraria or travel support from Novartis, Sanofi, SOBI, Takeda. CCL received honoraria or travel support from Gilead/Kite and Therakos. Consulting fees for advisory board from Gilead/Kite, Nektar Therapeutics. FB participated to AB and received speaker fees from NEOVII and SANOFI. PD reports consultancy for AbbVie, AstraZeneca, Beigene, BMS, Gilead, Miltenyi, Novartis, Riemser; speakers bureau for AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Novartis, Riemser, Roche; research support from Riemser (all to institution).
: The study was approved by the EBMT review board. Patients had to sign an informed consent document that permitted sharing of clinical data according to national rules.